Nothing Special   »   [go: up one dir, main page]

CL2022002766A1 - Anticuerpos anti-phf-pau y sus usos. - Google Patents

Anticuerpos anti-phf-pau y sus usos.

Info

Publication number
CL2022002766A1
CL2022002766A1 CL2022002766A CL2022002766A CL2022002766A1 CL 2022002766 A1 CL2022002766 A1 CL 2022002766A1 CL 2022002766 A CL2022002766 A CL 2022002766A CL 2022002766 A CL2022002766 A CL 2022002766A CL 2022002766 A1 CL2022002766 A1 CL 2022002766A1
Authority
CL
Chile
Prior art keywords
antibodies
phf
pau
tauopathies
antigen
Prior art date
Application number
CL2022002766A
Other languages
English (en)
Inventor
Jinquan Luo
Marc Mercken
Kolen Kristof Van
Rajkumar Ganesan
Sanjaya Singh
Sathyadevi Venkataramani
Porte Sherry La
Rupesh Nanjunda
Pharavee Jaiprasart
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2022002766A1 publication Critical patent/CL2022002766A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

Se describen anticuerpos monoclonales anti-PHF-tau y fragmentos de unión al antígeno de estos. Además, se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y usar los anticuerpos para tratar o prevenir afecciones, tales como tauopatías.
CL2022002766A 2020-04-08 2022-10-06 Anticuerpos anti-phf-pau y sus usos. CL2022002766A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063007118P 2020-04-08 2020-04-08
US202063026387P 2020-05-18 2020-05-18

Publications (1)

Publication Number Publication Date
CL2022002766A1 true CL2022002766A1 (es) 2023-04-21

Family

ID=78023121

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002766A CL2022002766A1 (es) 2020-04-08 2022-10-06 Anticuerpos anti-phf-pau y sus usos.

Country Status (19)

Country Link
US (1) US20230151083A1 (es)
EP (1) EP4132569A4 (es)
JP (1) JP2023521763A (es)
KR (1) KR20220166308A (es)
CN (1) CN115697393A (es)
AU (1) AU2021251486A1 (es)
BR (1) BR112022020410A2 (es)
CA (1) CA3179914A1 (es)
CL (1) CL2022002766A1 (es)
CO (1) CO2022015737A2 (es)
CR (1) CR20220505A (es)
DO (1) DOP2022000218A (es)
EC (1) ECSP22078815A (es)
IL (1) IL297231A (es)
MX (1) MX2022012628A (es)
PE (1) PE20230385A1 (es)
PH (1) PH12022553035A1 (es)
TW (1) TW202204402A (es)
WO (1) WO2021205359A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
IL315540A (en) * 2022-03-11 2024-11-01 Janssen Pharmaceutica Nv Multispecific antibodies and their uses
IL315544A (en) * 2022-03-11 2024-11-01 Janssen Pharmaceutica Nv Multispecific antibodies and their uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59024B1 (sr) * 2011-12-20 2019-08-30 Janssen Biotech Inc Anti-phf-tau antitela i njihove upotrebe
WO2016112078A2 (en) * 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
EP3319984A1 (en) * 2015-07-06 2018-05-16 UCB Biopharma SPRL Tau-binding antibodies
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها

Also Published As

Publication number Publication date
BR112022020410A2 (pt) 2023-01-03
WO2021205359A1 (en) 2021-10-14
CR20220505A (es) 2023-05-31
EP4132569A1 (en) 2023-02-15
EP4132569A4 (en) 2024-07-31
ECSP22078815A (es) 2022-11-30
CO2022015737A2 (es) 2023-02-27
IL297231A (en) 2022-12-01
MX2022012628A (es) 2023-01-11
AU2021251486A1 (en) 2022-12-08
CN115697393A (zh) 2023-02-03
KR20220166308A (ko) 2022-12-16
DOP2022000218A (es) 2023-04-30
US20230151083A1 (en) 2023-05-18
PE20230385A1 (es) 2023-03-06
TW202204402A (zh) 2022-02-01
PH12022553035A1 (en) 2024-05-13
JP2023521763A (ja) 2023-05-25
CA3179914A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
CL2022002766A1 (es) Anticuerpos anti-phf-pau y sus usos.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
AR053608A1 (es) Anticuerpos anti-gm-csf y usos de los mismos
CL2022001769A1 (es) Anticuerpos anti-cd73 y usos de estos.
JOP20170170A1 (ar) صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
CR20190330A (es) Anticuerpos anti-ox40 y sus usos
CO2021008997A2 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
UY39698A (es) Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2020006105A (es) Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
EA202190807A1 (ru) Антитела к синуклеину
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
BR112023020450A2 (pt) Anticorpos anti-cd19 e estruturas car-t
MX2020009277A (es) Anticuerpos anti-phf-tau y usos de estos.
EA202092122A1 (ru) Антитела против tip-1 и их применения
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2024009726A (es) Anticuerpos anti-il13ra2 y usos de estos.
AR130536A1 (es) Anticuerpos que se unen a cd228
CO2024012037A2 (es) Anticuerpos multiespecíficos y usos de estos
EA202092840A1 (ru) Антитела к cd33, биспецифические антитела к cd33/cd3 и их применение